Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LO-MAPT: Omega-3 for Cognitive Decline Prevention
NCT03691519Phase 3Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Apr 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eicosapentaenoic acid + docosahexaenoic acid in Alzheimer's disease (AD), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Composite Z-score of neuropsychological assessments at 18 months. Started Apr 2018; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03691519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03691519.